According to some clinical trials, PD-1/PD-L1 inhibitors could obtain good therapeutic effect in dMMR CRC patients and has been approved for treating dMMR CRC in clinic by the Food and Drug Administration (FDA) [22–24]. This evidence concerns the gene CD274 and colorectal carcinoma.